Skip to main content

INDV 6-K

Indivior Pharmaceuticals, Inc. (INDV)

6-K 2024-11-19 For: 2024-11-19
View Original
Added on April 10, 2026

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

________________________

Washington, D.C. 20549

_____________________

FORM 6-K

_____________________

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of November 2024

Commission File Number: 001-37835

________________________________________

Indivior PLC

________________________________________

10710 Midlothian Turnpike, Suite 125

North Chesterfield, Virginia 23235

(Address of principal executive office)

_______________________________

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit No. Description of Exhibit
99.1 Announcement sent<br>to the London Stock Exchange on November 19, 2024, titled<br>“Transaction in Own Shares”.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Indivior PLC
Date: November 19, 2024 /s/<br>Kathryn Hudson
Name:<br>Kathryn Hudson
Title:<br>Company Secretary

a6776m-2

Exhibit 99.1

INDIVIOR PLC

SHARE REPURCHASE PROGRAM

WEEKLY REPORT

November 19, 2024

INDIVIOR PLC ("Indivior") announces that it purchased for cancellation a total of 316,561 of its ordinary shares of $0.50 each through Morgan Stanley & Co. International Plc in the period from November 11, 2024, up to and including November 15, 2024, in connection with its $100m Share Repurchase Program. Aggregated information on the purchase of these shares can be found in the table below.

Following the purchase and cancellation of the above shares (including those purchased but not yet settled), Indivior has 126,526,967 ordinary shares of $0.50 each with voting rights in issue. There are no shares held in treasury.

The above figure (126,526,967) may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, Indivior under the FCA's Disclosure Guidance and Transparency Rules.

All repurchases by Indivior are "On Exchange" transactions (as such term is defined in the rules of the London Stock Exchange) and "on market" for the purposes of the Companies Act 2006.

Aggregated information

Trading<br>Date Trading<br>Venue Aggregated<br>daily volume (number of shares) Daily<br>weighted average purchase price of the shares (p)
12/11/2024 LSE 66,557 795.95
13/11/2024 LSE 51,916 802.56
13/11/2024 BATE 7,472 799.99
13/11/2024 CHIX 21,213 799.57
13/11/2024 AQUIS 2,929 798.17
14/11/2024 LSE 28,698 797.24
14/11/2024 BATE 9,444 797.15
14/11/2024 CHIX 37,533 798.20
14/11/2024 AQUIS 7,245 800.78
15/11/2024 LSE 29,175 791.25
15/11/2024 BATE 11,229 790.22
15/11/2024 CHIX 37,022 791.61
15/11/2024 AQUIS 6,128 795.63

Transaction details

In accordance with Article 5(1)(b) of the assimilated Market Abuse Regulation (EU) No 596/2014, as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018 and Commission Delegated Regulation (EU) 2016/1052, a full breakdown of the individual purchases of ordinary shares made by Morgan Stanley & Co. International Plc on behalf of Indivior during the above period as part of the Share Repurchase Program can be found at www.indivior.com/en/investors/shareholder-information/share-repurchase-program.

Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.

Contact:

Jason Thompson

Vice President, Investor Relations

1-804-402-7123